• SciSparc subsidiary NeuroThera Labs closed its purchase of about 54% of Israel-based CliniQuantum.
• NeuroThera issued 56,600,000 common shares valued at about CAD 9.46 million to acquire 56,375 CliniQuantum shares.
• Sellers can earn up to USD 2.5 million over three years, tied to patent filings and fundraising milestones.
• CliniQuantum develops quantum-based analytics for clinical trial data, aiming to identify patient subgroups that respond to therapies.
• Key asset is an exclusive worldwide license from Quantum X Labs covering a US provisional patent application in quantum Monte Carlo sampling.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scisparc Ltd. published the original content used to generate this news brief on June 04, 2026, and is solely responsible for the information contained therein.